SCHEMBL120400

SCHEMBL120400

O=S(=O)(NCc1ccccc1)c1ccc(Br)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
POLB P06746 1/20 0.59
KEAP1 Q14145 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 1/20 0.57
SLC12A2 P55011 1/20 0.57
SLC12A5 Q9H2X9 1/20 0.57
CA12 O43570 2/20 0.55
CA9 Q16790 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP19A1 P11511 3/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
ALDH1A1 P00352 3/20 0.53
HPGD P15428 1/20 0.53
HDAC2 Q92769 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31113705 0.88 PKM (0.65) PKMSMN1; SMN2POLBKEAP1KMT2A
SCHEMBL4883669 0.86 RAB9A (0.60) PKMSMN1; SMN2KMT2ALMNAALDH1A1
SCHEMBL117930 0.82 PKM (0.65) PKMSMN1; SMN2POLBKEAP1LMNA
SCHEMBL120482 0.82 LMNA (0.69) PKMKEAP1KMT2ALMNASLC12A2
SCHEMBL31113865 0.79 KMT2A (0.66) PKMSMN1; SMN2POLBKEAP1KMT2A
SCHEMBL2499052 0.79 PKM (0.69) PKMSMN1; SMN2POLBKEAP1KMT2A
SCHEMBL19197973 0.79 SMN1; SMN2 (0.69) PKMSMN1; SMN2POLBKEAP1KMT2A
SCHEMBL28836851 0.79 PKM (0.65) PKMPOLBKEAP1KMT2ALMNA
SCHEMBL3006563 0.78 ALDH1A1 (0.63) SMN1; SMN2KMT2ACA9CA1CA2
SCHEMBL2831966 0.78 CYP19A1 (0.78) PKMSMN1; SMN2POLBKEAP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 PKM 1399/4885SMN1; SMN2 1501/4885POLB 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.